ArticleAnnals of nuclear medicine2025

ΔBSIJ: a quantitative marker for early detection of medication-related osteonecrosis of the jaw in patients with prostate cancer receiving bone-modifying agents.

Hidetoshi Kokubun et al.PubMed ↗Publisher ↗

No numbers read from the abstract.